# Nifedipine (Adalat CR, BAY A1040) High Dose PK/PD Study

> **NCT00768560** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 35 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Nifedipine (Adalat CR, BAYA1040) 80mg OD
- **DRUG:** Nifedipine (Adalat CR, BAYA1040) 40mg BID
- **DRUG:** Nifedipine (Adalat CR, BAYA1040) 40mg OD

## Key facts

- **NCT ID:** NCT00768560
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2015-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00768560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00768560, "Nifedipine (Adalat CR, BAY A1040) High Dose PK/PD Study". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00768560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*